Covista Inc. (CVSA) · Oct 29, 2026 · Earnings
Beat — Adj. EPS $2.19 vs ~$1.86 consensus; revenue $511.5M vs ~$498M
Covista earnings beat published Q1 estimates, with enrollment-led growth lifting FY27 revenue and adjusted EPS guidance despite a planned CFO retirement.
Covista is in the middle of a healthcare-education expansion strategy, using Chamberlain, Walden, and its medical schools to grow enrollment and address the U.S. healthcare workforce shortage; Walden is currently the main growth engine, while Chamberlain is expanding campuses and employer partnerships.
The quarter cleared the published bar, not just the company’s own narrative. Revenue reached $511.5 million versus a published consensus near $498 million, while adjusted EPS was $2.19 versus roughly $1.86 expected. That makes this a genuine earnings beat, with the upside broad enough to support the guidance increase rather than relying on a one-off accounting item. (Financial Highlights)
| Metric | Q1 FY27 | Q1 FY26 | Consensus |
|---|---|---|---|
| Revenue (Financial Highlights) | $511.5M (+10.7%) | $462.3M | ~$498M |
| Adjusted EPS (Financial Highlights) | $2.19 (+25.1%) | $1.75 | ~$1.86 |
| Adjusted EBITDA (Financial Highlights) | $131.2M (+17.1%) | $112.0M | |
| Total enrollment (First quarter highlights) | 104,713 (+7.6%) | 97,338 |
Growth is increasingly concentrated in Walden, but the portfolio is still moving forward. Walden enrollment rose 12.8% and revenue rose 14.1%, while Medical and Veterinary produced 10.0% revenue growth and 33.0% operating-income growth. Chamberlain remains the weaker spot: enrollment grew only 1.3% and operating income 4.4%, with its margin slipping to 13.9% from 14.3%. 〔0〕
Management raised the full-year framework, making the beat more consequential. FY27 revenue guidance moved to $2.060 billion-$2.095 billion from $2.050 billion-$2.090 billion, and adjusted EPS guidance moved to $9.00-$9.20 from $8.90-$9.15. The increases are modest, but they confirm that the enrollment momentum is translating into a higher earnings base rather than merely pulling results forward. (Fiscal Year 2027 Outlook)
Capital allocation and financing reinforce the operating result. Covista repurchased $84 million of shares, reduced its Term Loan B pricing by 25 basis points, and ended the quarter at 0.5x net leverage. Those actions improve financial flexibility, although cash fell to $222.2 million after buybacks and $163 million of debt repayment. (Capital allocation; Balance Sheets; Cash Flow statement)
The CFO retirement is a manageable but real execution variable. Robert Phelan will remain until a successor is named, and the filing describes the move as planned with no immediate change in responsibilities; the risk is therefore succession continuity, not an abrupt financial-control disruption. (Management Update) 〔1〕
Bottom line: This is a real beat with a modest but credible guidance lift, led by Walden and improving margins. The CFO transition adds a watch item, but it does not outweigh the stronger operating trajectory shown in this filing.
CFO successor announcement
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!